Drug intelligence / Profile preview

Mencevax ACW

Development stage: Phase 3
Lead developer: GSK
Modality: Vaccines & Immunotherapeutics
Administration: Subcutaneous

Overview

Mencevax ACW is a polysaccharide meningococcal vaccine indicated for active immunization against meningococcal disease caused by Neisseria meningitidis serogroups A, C, and W135. It works by stimulating the body's immune system to produce protective antibodies against the specific polysaccharide antigens of these bacterial serogroups. Originally developed by GlaxoSmithKline, the vaccine was acquired by Pfizer in 2015.

Brand names: Mencevax ACW
Other names: Mencevax Group A, C and W135 polysaccharide meningococcal vaccineMeningococcal vaccine groups A C W135

Targets

Neisseria meningitidis group C capsular polysaccharideMenW CPS (Neisseria meningitidis serogroup W capsular polysaccharide)NmA CPS (Neisseria meningitidis group A capsular polysaccharide)

Beyond the preview

Go deeper on Mencevax ACW.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mencevax ACW.

Explore the full profile